| ACMS3 | Acyl-CoA synthetase medium-chain 3 |
| AMPK | AMP-activated protein kinase |
| AR | Androgen receptor |
| BMI | Body mass index |
| CAA | Cancer-associated adipocytes |
| Cav-1 | Caveolin-1 |
| CM | Cutaneous melanoma |
| CRP | C-reactive protein |
| ER | Estrogen receptor |
| FAs | Fatty acids |
| FASN | Fatty acid synthase |
| FFA | Free fatty acid |
| ICI | Immune checkpoint inhibitor |
| IGF-1 | Insulin-like growth factor-1 |
| IL-1 | Interleukin-1 |
| IL-6 | Interleukin-6 |
| IL-18 | Interleukin-18 |
| irAEs | Immune-related adverse events |
| LEF-1 | Lymphoid enhancer-binding factor 1 |
| LDL | Low-density lipoproteins |
| mTOR | Mammalian target of rapamycin |
| OS | Overall survival |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed death-ligand 1 |
| PFS | Progression-free survival |
| PPARα | Peroxisome proliferator-activated receptor alpha |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| ROS | Reactive oxygen species |
| TME | Tumor microenvironment |
| TNF-α | Tumor necrosis factor alpha |
| TNM | Tumor, Node, Metastasis |
| TREM2 | Triggering receptor expressed on myeloid cells 2 |
| VEGF | Vascular endothelial growth factor |
| Wnt5a | Wnt family member 5A |
| β-cat | Beta-catenin |